AR123160A1 - COMPOSITIONS AND METHODS TO INHIBIT THE EXPRESSION OF LPA - Google Patents
COMPOSITIONS AND METHODS TO INHIBIT THE EXPRESSION OF LPAInfo
- Publication number
- AR123160A1 AR123160A1 ARP210102190A ARP210102190A AR123160A1 AR 123160 A1 AR123160 A1 AR 123160A1 AR P210102190 A ARP210102190 A AR P210102190A AR P210102190 A ARP210102190 A AR P210102190A AR 123160 A1 AR123160 A1 AR 123160A1
- Authority
- AR
- Argentina
- Prior art keywords
- lpa
- expression
- inhibit
- region
- antisense strand
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
En la presente se proporcionan oligonucleótidos que inhiben la expresión de la apolipoproteína (a) (LPA). También se proporcionan composiciones que los incluyen y sus usos, particularmente usos relacionados con el tratamiento de enfermedades, trastornos y/o afecciones asociadas con la expresión de LPA. Reivindicación 1: Un oligonucleótido de ARNi para reducir la expresión de LPA, el oligonucleótido que comprende una cadena sentido y una cadena antisentido, donde la cadena sentido y la cadena antisentido forman una región dúplex, donde la cadena antisentido comprende una región de complementariedad con una secuencia objetivo de ARNm de LPA de cualquiera de las SEQ ID Nº 4 - 387, y donde la región de complementariedad tiene al menos 15 nucleótidos contiguos de longitud. Reivindicación 62: Una composición farmacéutica que comprende el oligonucleótido de ARNi de cualquiera de las reivindicaciones 1 a 60, y un portador, agente de administración o excipiente farmacéuticamente aceptable.Provided herein are oligonucleotides that inhibit the expression of apolipoprotein(a) (LPA). Also provided are compositions including them and their uses, particularly uses related to the treatment of diseases, disorders and/or conditions associated with the expression of LPA. Claim 1: An RNAi oligonucleotide for reducing the expression of LPA, the oligonucleotide comprising a sense strand and an antisense strand, where the sense strand and the antisense strand form a duplex region, where the antisense strand comprises a region of complementarity with a LPA mRNA target sequence of any of SEQ ID NOs: 4-387, and wherein the region of complementarity is at least 15 contiguous nucleotides in length. Claim 62: A pharmaceutical composition comprising the RNAi oligonucleotide of any of claims 1 to 60, and a pharmaceutically acceptable carrier, delivery agent or excipient.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063061676P | 2020-08-05 | 2020-08-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR123160A1 true AR123160A1 (en) | 2022-11-02 |
Family
ID=84578031
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210102190A AR123160A1 (en) | 2020-08-05 | 2021-08-05 | COMPOSITIONS AND METHODS TO INHIBIT THE EXPRESSION OF LPA |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR123160A1 (en) |
-
2021
- 2021-08-05 AR ARP210102190A patent/AR123160A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2537568T3 (en) | New drugs for inhibition of genetic expression | |
| PE20210921A1 (en) | ARNI AGENTS AS INHIBITORS OF SERPINE 1 TRANSCRIPTION AND COMPOSITIONS THAT INCLUDE THEM | |
| BR112015024729A2 (en) | modified beta oligonucleotide for use in a method of preventing and / or treating an ophthalmic disease | |
| CL2013003105A1 (en) | Microarn compounds comprising modified nucleoside sequences, mir-21 inhibitors; uses of the compounds to modulate the activity of mir -21 and to prepare a drug to treat fibrosis, wounds or cancer | |
| AR084319A1 (en) | MicroRNA INHIBITORS (miRNA OR miR) THAT INCLUDE BLOCKED NUCLEOTIDES | |
| PE20230179A1 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF A DISORDER ASSOCIATED WITH ANGIOTENSINOGEN (AGT) | |
| PE20212248A1 (en) | OLIGOMERIC MOLECULE OF NUCLEIC ACID AND USE OF IT | |
| PE20211912A1 (en) | USE OF FUBP1 INHIBITORS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | |
| AR123420A1 (en) | DUX4 INHIBITORS AND METHODS OF USE THEREOF | |
| PE20211749A1 (en) | ANTI-SENSE OLIGONUCLEOTIDES ACTING ON ALPHA-SINUCLEIN, AND USES OF THESE | |
| FR2790757B1 (en) | OLIGONUCLEOTIDES CONTAINING AN ANTI-SENSE SEQUENCE STABILIZED BY A SECONDARY STRUCTURE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME. | |
| AR124713A1 (en) | COMPOSITIONS AND METHODS TO INHIBIT THE EXPRESSION OF GENES IN THE CENTRAL NERVOUS SYSTEM | |
| AR123679A1 (en) | RNAi COMPOSITIONS AGAINST THE SNCA GENE AND METHODS OF USE THEREOF TO TREAT OR PREVENT NEURODEGENERATIVE DISEASES ASSOCIATED WITH SNCA | |
| AR123160A1 (en) | COMPOSITIONS AND METHODS TO INHIBIT THE EXPRESSION OF LPA | |
| AR124302A1 (en) | TAU TARGETING OLIGONUCLEOTIDE GAPMERS | |
| AR125992A1 (en) | COMPOSITIONS AND METHODS FOR INHIBITING THE EXPRESSION OF MITOCHONDRIAL AMIDOXIMA REDUCTION COMPONENT 1 (MARC1) | |
| AR079649A1 (en) | COMPOSITIONS AND METHODS TO INHIBIT THE EXPRESSION OF GENES IL-18 | |
| AR125230A1 (en) | COMPOSITIONS OF ANTI-HUNTINGTIN (HTT) RNAi AGENTS AND THEIR METHODS OF USE | |
| PE20241132A1 (en) | ARNI COMPOSITIONS AND METHODS TO SILENCE ANGIOTENSINOGEN (AGT) | |
| AR123152A1 (en) | COMPOSITIONS AND METHODS TO INHIBIT THE EXPRESSION OF PLP1 | |
| AR123138A1 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC SYNDROME | |
| AR129311A1 (en) | COMPOSITIONS AND METHODS FOR INHIBITING MAPT EXPRESSION | |
| AR126771A1 (en) | RNAi COMPOSITIONS AGAINST FACTOR XII (F12) AND THEIR METHODS OF USE | |
| AR129312A1 (en) | COMPOSITIONS AND METHODS FOR INHIBITING SNCA EXPRESSION | |
| AR124636A1 (en) | COMPOSITIONS AND METHODS TO INHIBIT THE EXPRESSION OF a-1 ANTITRYPSIN |